On the stock market since 2026, it operates in the world of health and science. It has 21 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades below its recent peak — about 14% off the top. A pullback, not a collapse.
There is $141.9M in the vault; even if every debt were paid off, $141.9M would remain.
The average analyst price target is $163 — 46% above today’s price.
A loss of $70.0M against $0 in annual sales.
At the current pace of spending, the cash lasts about 2 years. After that, the company needs to find new money.
On our five-subject report card, MANE sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: MANE is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (56/100) says the stock isn’t cheap.